Amend claim 3 as follows:

3. (amended) A device for separating CD4-positive cells, comprising a chimera antibody, wherein the antibody comprises an H chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 1 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID NO. 2 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 3 in the Sequence Listing, an L chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 4 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID No. 5 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 6 in the Sequence Listing, and an Fc region of a human type, and wherein said chimera antibody is bound to a water-insoluble carrier in the form of fiber.

Amend claim 4 as follows:

4. (amended) A device for separating CD4-positive cells, comprising a single chain antibody, wherein the antibody comprises an H chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 1 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID NO. 2 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 3 in the Sequence

Listing, and an L chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 4 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID No. 5 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 6 in the Sequence Listing, and wherein said single chain antibody is bound to a water-insoluble carrier in the form of fiber.

Amend claim 11 as follows:

11. (amended) A method for separating or detecting human CD4-positive using an antibody selected from the group consisting of a chimera antibody, a single chain antibody, and combinations thereof, wherein said antibody is bound to a water-insoluble carrier in the form of fiber directly or indirectly, comprising:

contacting a cell suspension comprising CD4-positive cells with said water-insoluble carrier,

separating said cell suspension and said carrier, and

obtaining said water-insoluble carrier which is bound to CD4-positive cells on its surface.

Claim 12 has been amended as follows:

12. (amended) A method for separating or detecting human CD4-positive cells, using a chimera antibody to CD4

molecules, wherein the antibody comprises an H chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 1 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID NO. 2 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 3 in the Sequence Listing, an L chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 4 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID No. 5 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 6 in the Sequence Listing, and an Fc region of a human type, comprising:

contacting a cell suspension comprising CD4-positive cells with said water-insoluble carrier,

separating said cell suspension and said carrier, and

obtaining said water-insoluble carrier which is bound to CD4-positive cells on said cell surface.

Claim 13 has been amended as follows:

13. (amended) A method for separating or detecting human CD4-positive cells, using a single chain antibody to a CD4-molecule, wherein the antibody comprises an H chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 1 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID NO. 2 in the Sequence

Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 3 in the Sequence Listing, and an L chain variable region of which CDR-1 is an amino acid sequence represented by Sequence ID No. 4 in the Sequence Listing, CDR-2 is an amino acid sequence represented by Sequence ID No. 5 in the Sequence Listing, and CDR-3 is an amino acid sequence represented by Sequence ID No. 6 in the Sequence Listing, comprising:

contacting a cell suspension comprising CD4-positive cells with said water-insoluble carrier,

separating said cell suspension and said carrier, and

obtaining said water-insoluble carrier which is bound to CD4-positive cells on said cell surface.

Amend claim 30 as follows:

30. (amended) The device for separating cells according to claim 2, wherein the antibody selected from the group consisting of a chimera antibody, a single chain antibody, and combinations thereof is bound to an active group of a polypropylene nonwoven fabric reacted with a haloacetaminomethylating agent.

Amend claim 32 as follows:

32. (amended) The device for separating cells according to claim 3, wherein the antibody is bound to an active

group of a polypropylene nonwoven fabric reacted with a haloacetaminomethylating agent.

Amend claim 34 as follows:

34. (amended) The device for separating cells according to claim 4, wherein the antibody is bound to an active group of a polypropylene nonwoven fabric reacted with a haloacetaminomethylating agent.